Matt has 20 years experience creating and executing acquisition and organic growth strategies for private equity-backed (Warburg Pincus; KKR) and large public companies (Covidien). He enjoys working as an independent consultant so he can provide flexible bandwidth and additional expertise to help entrepreneurial management teams create value for their companies. He brings a practical approach to projects grounded in a strong financial foundation.
Served as the head of the Program Management Office, in charge of planning and managing the move of five facilities and over 450 positions from New Jersey to San Diego.
Led the sourcing, due diligence activities, and agreement negotiations for the divestiture of the IRMA blood-gas division, and the sale and short-term leaseback of two Accriva-owned buildings in Edison, NJ.
Developed the three year strategic plan for Accriva and led the portfolio management activities, culminating in the final product roadmap.
Created the management presentations and managed the due diligence process for the sale of Accriva.
Managed the Instrument Assembly and Service departments (25+ employees) on an interim basis for fourteen months. Eliminated over $600K of new instrument back-orders, reduced service turnaround time from sixty days to under fifteen days, and eliminated five positions to reduce overall operating costs.
Directed the Supply Chain function (nine employees) on an interim basis for a combined four months. Implemented new processes and controls to reduce chronic component stock-out situations.
Vice President of Business Development, Strategy, and Portfolio Management
2007 - 2010
Joined Covidien to lead the Business Development function for the $1.3 billion Patient Care and Safety Products Division. Promoted within one year to form the Global Strategic Development Group, combining the existing Business Development, Strategy, and Portfolio Management, and Upstream / Strategic Marketing functions within the division.
Developed comprehensive market entry strategies for the Deep Vein Thrombosis, Chronic Venous Insufficiency, Peripheral Arterial Disease, and Interventional Neurovascular market segments by enlisting Key Opinion Leaders and performing primary and secondary market research.
Created the business plan and executed the initial acquisitions to form the Vascular Therapies Global Business Unit in 2009. Vascular Therapies was the first new growth platform developed within Covidien since 2001, and over $3.0 Billion was committed to fund the new platform over two years.
Completed six acquisition, licensing, distribution, and divestiture transactions.
Defined the overall strategy for the division, including developing annual strategic plans and quarterly portfolio reviews, and allocating resources across product segments.
Conducted capability gap analyses based on medical device market trends and created capability and company acquisition target lists.
Sourced acquisitions by proactively contacting business owners and "selling" them on the benefits of an acquisition by Accellent / MedSource.
Managed due diligence process, including dealing with internal members and external advisers (accountants, tax, legal, etc.).
Built all financial valuation models used to evaluate the acquisition targets. Models included full income, balance sheet, and cash flow statements, in addition to detailed build-ups for revenue and expenses.
Negotiated acquisition agreements with the selling parties.
Focus areas: Valuation, Financial Modeling, Post-merger Integration, Capital Raising, Due Diligence, Portfolio Management, Strategic Planning, Mergers & Acquisitions (M&A)
2005 - 2005
Proactively sourced the investment for the private equity firm by directly contacting the CEO of Paragon Medical.
Proactively sourced the add-on acquisition for Paragon (use of proceeds from the private equity investment) by contacting numerous potential acquisition targets.
Created financial valuation models used in the analysis of the acquisition.
Led the management team and external advisers through the due diligence for the add-on acquisition.
Prepared presentations summarizing the due diligence findings and integration plan used for Board of Director approval.